- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00674505
Safety & Performance Study of Lumen Biomedical's FiberNet Distal Protection System for the Treatment of Renal Artery Stenosis (FORTRESS)
February 16, 2010 updated by: VIVA Physicians
FiberNet Renal Artery Embolic Protection Study: A Prospective, Single-arm Feasibility Trial of Renal Artery Distal Protection Using the Lumen Biomedical FiberNet Embolic Protection System
To evaluate the procedural safety and filter efficiency of the FiberNet® Embolic Protection System when used in conjunction with the Boston Scientific Express SD Stent System for primary stenting of ostial atherosclerotic renal lesions in patients with atherosclerotic renal artery stenosis.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Jose, California, United States, 95123
- VIVA Physicians Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥ 18 and ≤ 85 years.
- Subject or subject's legal representative have been informed of the nature of the study, agrees to participate and has signed an IRB approved consent form.
- Subject understands the duration of the study and it's follow up visit requirements.
Unilateral or bilateral atherosclerotic de novo renal artery stenosis (RAS) associated with any or all of the following:
- SBP >140 despite ≥3 anti-hypertensive medications
- Estimated Glomerular Filtration Rate (eGFR) ≥30-≤70 cc/min calculated using the Modified Diet in Renal Disease (MDRD) formula
- Recurrent episodes of decompensated heart failure
- Recurrent episodes of "flash" pulmonary edema
Angiographic Inclusion Criteria
- ≥70% <100% renal artery stenosis (by visual estimate) involving unilateral, bilateral renal arteries or solitary renal artery.
- Renal pole-to-pole length >7cm.
- Lesion ≤15 mm from the aorto-ostial junction.
- Renal artery reference lumen diameter ≥3.5 - ≤7 mm for FiberNet placement.
Exclusion Criteria:
Clinical Exclusion Criteria
- Estimated life expectancy <12 months.
- Estimated Glomerular Filtration Rate (eGFR) <30 cc/min.
- Renal pole-to-pole length <7cm on side of diseased kidney.
- No history of transplanted kidneys or polycystic kidney disease.
- Uncontrolled hypercoagulability.
- Known allergies or sensitivities to heparin, aspirin, other anti-coagulant/antiplatelet therapies, nitinol and stainless steel.
- Known allergy to contrast media that cannot adequately be pre-medicated prior to study procedure.
- Patient refuses possible temporary or permanent hemodialysis.
- Refuses possible surgery for repair of access site or renal artery.
- Known severe coronary or carotid disease likely to require surgical treatment after enrollment or during follow-up period.
- Uncompensated congestive heart failure.
- Current enrollment in any investigational study wherein patient participation has not been completed.
- Cardiovascular surgical or cardiovascular interventional procedures (including, but not limited to, aortic, renal, cardiac, carotid, femoro-popliteal, and below the knee) within 30 days prior to enrollment in this study.
- Planned or predicted cardiovascular surgical or interventional procedures outside of the affected renal artery (including, but not limited to, aortic, renal, cardiac, carotid, contralateral femoro-popliteal, and contralateral below the knee) within 30 days after entry into this study and prior to completion of the 30 day follow-up.
- Pregnancy, breast-feeding or plans to become pregnant in female of child bearing potential.
- Any patient who in the opinion of the investigator would not be a good candidate for enrollment.
Angiographic Exclusion Criteria
- Early bifurcation of the main renal artery preventing complete embolic protection of the kidney with the FiberNet.
- Fibromuscular Dysplasia.
- Presence of thrombus at the lesion site.
- Non-ostial atherosclerosis (lesion >15mm from the renal ostium).
- Subintimal guidewire placement resulting in dissection of the renal artery or aorta, or perforation of the renal artery or aorta prior to deployment of the device.
- Severe calcification likely to prevent the passage of the device. -
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Treatment, Open label, Single Group Assignment
|
to demonstrate the safety and filter efficiency of the Lumen Biomedical FiberNet Embolic Protection System during the performance of primary renal stenting in the treatment of pts with a high grade ostial atherosclerotic renal lesion(s).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Measurable amount of macro/micro atheroma particle captured by the FiberNet EPS as adjudicated by core lab analysis.
Time Frame: Various secondary endpoints evaluated at 30 days and 6 months
|
Various secondary endpoints evaluated at 30 days and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression to temporary/permanent renal replacement therapy and Analysis of debris captured by the FiberNet® Embolic Protection System
Time Frame: most at 30 days and 6 months
|
most at 30 days and 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2008
Primary Completion (Anticipated)
June 1, 2009
Study Registration Dates
First Submitted
May 6, 2008
First Submitted That Met QC Criteria
May 7, 2008
First Posted (Estimate)
May 8, 2008
Study Record Updates
Last Update Posted (Estimate)
February 17, 2010
Last Update Submitted That Met QC Criteria
February 16, 2010
Last Verified
February 1, 2010
More Information
Terms related to this study
Other Study ID Numbers
- G070189/S002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lumen Biomedical FiberNet Embolic Protection System
-
Lumen BiomedicalCompletedCarotid Artery StenosisGermany
-
Lumen BiomedicalCompletedCarotid Artery StenosisUnited States
-
TransAortic Medical, Inc.Completed
-
W.L.Gore & AssociatesCompletedCardiovascular Diseases | Vascular Diseases | Cerebrovascular Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Arterial Occlusive Diseases | Pathological Conditions, Anatomical | Constriction, Pathologic | Carotid Stenosis | Carotid Artery DiseasesUnited States
-
AorticLab SrlMeditrial Europe Ltd.CompletedAortic Valve Stenosis | Intracranial Embolism and ThrombosisItaly, Belgium
-
Silk Road MedicalCompletedCarotid Artery DiseasesGermany
-
EmStop IncBright Research PartnersRecruitingAortic Valve StenosisUnited States
-
Abbott Medical DevicesCompleted
-
InspireMDTerminatedST Elevation Myocardial InfarctionNetherlands
-
Fogarty Clinical Research Inc.Abbott Medical Devices; Helen Kay Foundation; Northern Michigan Hospital Foundation...Unknown